Search research articles
Contact Us
Filters
Showing results (81-90 of 109) with videos related to
Page
of 11
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 12, 2017
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study
David J Moore, Sonia Jain, Michael P Dubé, et al.
Plos One
|
February 9, 2023
Prevalence of and risk factors for Human Immunodeficiency Virus (HIV) infection in entrants and residents of an Ethiopian prison
Eliyas Tsegaye Sahle, Wondwossen Amogne, Tsegahun Manyazewal, et al.
Infectious Diseases and Therapy
|
March 9, 2021
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
The Journal of Infectious Diseases
|
August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359
Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 21, 2014
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens
Yu Zheng, Michael D Hughes, Shahin Lockman, et al.
International Journal of Epidemiology
|
February 12, 2008
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems
Mari M Kitahata, Benigno Rodriguez, Richard Haubrich, et al.
Lancet (London, England)
|
April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.
The Journal of Antimicrobial Chemotherapy
|
November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV
Brookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 17, 2021
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States
Jill Blumenthal, Sonia Jain, Feng He, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2013
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder
Ronald J Ellis, Scott Letendre, Florin Vaida, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 109) with videos related to
Sort By:
Page
of 11
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 12, 2017
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study
David J Moore, Sonia Jain, Michael P Dubé, et al.
Plos One
|
February 9, 2023
Prevalence of and risk factors for Human Immunodeficiency Virus (HIV) infection in entrants and residents of an Ethiopian prison
Eliyas Tsegaye Sahle, Wondwossen Amogne, Tsegahun Manyazewal, et al.
Infectious Diseases and Therapy
|
March 9, 2021
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Franco Maggiolo, Giuliano Rizzardini, Jean-Michel Molina, et al.
The Journal of Infectious Diseases
|
August 27, 2002
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359
Roy M Gulick, X Joan Hu, Susan A Fiscus, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 21, 2014
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens
Yu Zheng, Michael D Hughes, Shahin Lockman, et al.
International Journal of Epidemiology
|
February 12, 2008
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems
Mari M Kitahata, Benigno Rodriguez, Richard Haubrich, et al.
Lancet (London, England)
|
April 10, 2007
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, et al.
The Journal of Antimicrobial Chemotherapy
|
November 25, 2010
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV
Brookie M Best, Peter P Koopmans, Scott L Letendre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 17, 2021
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States
Jill Blumenthal, Sonia Jain, Feng He, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 20, 2013
Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder
Ronald J Ellis, Scott Letendre, Florin Vaida, et al.
Page
of 11